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ABSTRACT: Atenolol is a hypertension drug that has a low solubility 
characteristic in water and gastric fluid. The rate of absorption of the drug 
with poor solubility characteristics is determined by the dissolution 
process. In this study, an attempt has been conducted to increase the 
dissolution of atenolol by increasing its solubility. The solubility of 
atenolol has been enhanced by the inclusion complex using β-
cyclodextrin made by several methods (physical mixing, kneading, and 
solvent evaporation). Evaluation and characterization of atenolol-β-
cyclodextrin inclusion complex consist of drug content, dissolution test, 
Fourier Transformed Infrared analysis (FT-IR), Differential Scanning 
Calorimetry (DSC), X-ray Diffraction (XRD) and Scanning Electron 
Microscope (SEM). The results of the drug content analysis, dissolution 
test, and characterization showed that atenolol- β-cyclodextrin inclusion 
complex, which has been made by the solvent evaporation method was 
the best approach. Therefore, a solvent evaporation method was chosen to 
formulate orally disintegrating tablets of atenolol-β-cyclodextrin using 
direct compression technique. Orally disintegrating tablets of atenolol-β-
cyclodextrin were prepared using crospovidone as disintegrant. The 
results of pre-compression test and the post-compression test revealed 
that orally disintegrating tablets of atenolol-β-cyclodextrin inclusion 
complex disintegrate within 8.17 ± 0.41 sec. In-vitro dispersion time in 
simulated saliva was found to be 45.33 ± 0.58 sec and the percentage of 
atenolol dissolved from this formula was 92.22% in 30 min. Hence, this 
formula shows good physicochemical characteristics and fulfill 
pharmaceutical quality requirements of orally disintegrating tablet. 
INTRODUCTION: Atenolol is a drug to treat 
high blood pressure and has been widely used in 
hypertension therapy 
1
. Atenolol is slightly soluble 
in water.  
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The solubility of atenolol in water (25 °C) is 
approximately 13.3 mg/ml
2
. Low solubility 
characteristic of atenolol in water and gastric fluid 
caused the bioavailability of atenolol is about 50% 
following oral administration 
1
. The rate of 
absorption of the drugs which have low solubility 
characteristics determined by the rate of dissolution 
3
.  
The rate of dissolution can be increased by several 
methods such as decrease the particle size using 
micronization and nanoparticle techniques, solid 
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dispersion, salt formation, co-crystal, inclusion 
complex, etc. 
4, 5
 Inclusion complex is one of the 
approaches which has been used in the 
pharmaceutical field to improve the dissolution of 
poorly soluble drugs, taste masking of bitter drugs, 
and enhance the stability of several drugs 
6, 7
. 
Cyclodextrins are commonly used in the inclusion 
complex system because of its structure. 
Cyclodextrins are cyclic oligosaccharides consist of 
a macrocyclic ring of glucose subunits joined by α-
1, 4 glycosilic bonds 
8
. Cyclodextrins have several 
types regarding the number of glucopyranose units. 
In general, Cyclodextrins which consist of 6 (αCD), 
7 (βCD), or 8 (ϒCD) (α-1,4) -linked D-
glucopyranose units are widely used as host 
molecules in inclusion complex approach 
9
. 
Cyclodextrins in the three-dimensional structure 
described as a truncated cone with a hydrophilic 
exterior. The interior structure of cyclodextrins 
molecules consists of carbon groups of 
glucopyranose units; therefore the interior is more 
hydrophobic compared to the exterior part 
9, 10
. 
Regarding its structure, cyclodextrins can induce 
poorly soluble drugs in their cavity. While the 
exterior part contact with the medium, 
cyclodextrins will reveal the drugs which are 
entrapped in their cavity. Through an inclusion 
complex approach, cyclodextrins molecules can 
convert poorly soluble crystalline drugs into water-
soluble amorphous drug/cyclodextrins complexes 
The results from the previous research revealed that 
β-cyclodextrins was the most commonly employed 
in inclusion complex formation. The size cavity of 
β-cyclodextrins are suitable for the majority of 
drugs; therefore β-cyclodextrins can entrap the 
hydrophobic drugs well. Another reason for the use 
of β-cyclodextrins is the ease of its production and 
low cost 
10
. The big molecular cavity of β-
cyclodextrins increases the possibilities of the drug 
to be entrapped in the cavity. In general, one 
molecule of cyclodextrins will trap one molecule of 
the drug in their cavity 
11
. The ability of β-
cyclodextrins to form inclusion complex is 
influenced by the size, molecular weight, shape, 
and the characteristics of the drug 
11
. The inclusion 
complex of drug molecules with β-cyclodextrins 
can affect several pharmacokinetic characteristics 
of the drug, including (i) enhancement of the 
dissolution process for poorly soluble drugs, 
therefore improves the bioavailability of these 
drugs, (ii) reducing the toxicity of the drugs 
through application of the lower doses, and (iii) 
control the release of the drugs 
12
. 
The interaction between cyclodextrins as host 
molecules and the drugs as guest molecules are 
mainly through hydrophobic interactions, 
electronic effects, van der Walls forces, and steric 
factors. Hydrogen bonds also play a significant role 
in the cylclodextrins cavity to entrap the drug 
molecules 
13
. An inclusion complex of atenolol and 
β-cyclodextrins is promising to develop in order to 
increase the solubility of atenolol, hence the 
dissolution rate of atenolol will be enhanced. 
Moreover, an inclusion complex of atenolol with β-
cyclodextrinsis also giving opportunities for pre 
gastric absorption of atenolol 
14
. An inclusion 
complex of atenolol with β-cyclodextrin in 1:1 ratio 
was the best ratio, based on the evidence from 
previous studies 
15
. In this study, an inclusion 
complex of atenolol with β-cyclodextrins was 
prepared using a 1:1 ratio. The preparation method 
to produce inclusion complex determines the 
characteristics of the obtained inclusion complex, 
hence it must be studied to find the most 
appropriate method.  
The objective of this study is to prepare inclusion 
complexes of atenolol-β-cyclodextrins by different 
methods such as physical mixture, kneading, and 
solvent evaporation method. The inclusion 
complexes which are obtained from each method 
are then characterized to evaluate the thermal 
characteristic by differential scanning calorimetry 
(DSC). The crystallographic state of these inclusion 
complexes is also observed by X-ray powder 
diffractometry (XRD). Fourier transform infrared 
(FT-IR) apply to predict the possible interaction 
between atenolol and β-cyclodextrins.  
The morphology of the inclusion complex is 
evaluated by Scanning Electron Microscopy 
(SEM). The inclusion complex, which performs the 
best characteristics, then formulated into orally 
disintegrating tablets to increase patient 
compliance, especially in geriatric patients. Orally 
disintegrating tablets are characterized by high 
porosity, low density, and low hardness. When 
administered, an in-situ suspension is created in the 
oral cavity as the tablet disintegrates and is 
subsequently swallowed.  
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Tablets were prepared by using crospovidone as a 
disintegrant, aspartam, mannitol direct compress, 
Avicel PH 102
®
, mint flavor, magnesium stearate, 
and Aerosil
®
. Crospovidone was added to facilitate 
drug release and consequently improve the 
solubility of the drugs 
16
. Tablets were prepared by 
using a direct compression technique. The direct 
compression method is chosen because this method 
is simple and cost-effective 
17
. 
MATERIALS AND METHODS: 
Materials: Materials that were used in this study 
consists of atenolol pharmaceutical grade(p.g) 
(Refarmed Chemicals, Lugono Switzerland), β-
cyclodextrin (Roquette, France), ethanol (EtOH)pro 
analysis (p.a) (Merck), crospovidone (Kollidon® 
CL) p.g (BASF South East Asia Pre-Ltd), 
magnesium stearate p.g (Faci Asia Pacific PTE 
LTD), aspartame f.g (Ajinomoto Co. Inc.), aqua 
demineralisata (Laboratorium of qualitative 
chemistry University of Surabaya), manitol DC p.g 
(Roquette Freses, France), aerosil p.g (Brataco), 
mint flavor f.g (KH Roberts), sodium dihydrogen 
phosphate (NaH2PO4.2H2O) p.a (Merck), disodium 
hydrogen phosphate (Na2HPO4.12H2O) p.a 
(Merck), natrium acetate trihidrate (CH3COONa) 
p.a. (Riedel), acetic acid glacial (CH3COOH) p.a 
(Merck), methanol (MeOH) pro-HPLC 
(Mallinckrodt Chemicals), Avicel PH 102
®
 p.g 
(Mingtai Chemical Co. LTD), talk (Brataco), and 
filter paper No 41 (Whatmann
®
)    
Methods: 
Preparation of atenolol-β-cyclodextrin Inclusion 
Complex: The Inclusion complex of an atenolol-β-
cyclodextrin was prepared using a 1:1 ratio. Three 
different methods (physical mixture, kneading, and 
solvent evaporation method) have been utilized to 
prepare these inclusion complexes. 
Physical Mixture: The physical mixture of 
atenolol and β-cyclodextrin was prepared by 
mixing individual components using a mortar and a 
stamper until a homogeneous mixture was 
obtained. This mixture then stored in airtight 
containers.  
Kneading Method: Kneading method was the first 
method to prepare the inclusion complex of 
atenolol-β-cyclodextrin. A homogeneous mixture 
of atenolol and β-cyclodextrin is kneaded by 
ethanol to obtain the slurry mass. The slurry mass 
was grinding for 1 h until the solvent evaporated to 
produce a paste-like mass. This paste then dried at 
50 °C in a tray dryer for 4 h. The dried inclusion 
complex powder, then sieved using sieve No. 60 
and stored in airtight containers 
18
.  
Solvent Evaporation Method: The initial step to 
prepare the inclusion complex by this method was 
dissolved atenolol in ethanol, continuing with the 
addition of β-cyclodextrin into this solution. This 
mixture was stirred for 2 h using a magnetic stirrer, 
then this mixture was placed in a water bath (90 
°C) to evaporate the solvent. The inclusion 
complexes were obtained as a crystalline powder 
pulverized. The inclusion complexes were sieved 
by using siever no. 60 and stored in airtight 
containers until further use 
18
.  
Characterization of atenolol-β-cyclodextrin 
Inclusion Complex: 
Fourier Transform Infrared Spectrophotometry 
(FT-IR): The interaction between atenolol and β-
cyclodextrin was observed by the FT-IR 
transmission spectrum of atenolol, β-cyclodextrin, 
and inclusion complex using the potassium 
bromide (KBr) disc technique 
2, 14
. All the spectrum 
acquired were scanned between 400 and 4000 cm
-1
.  
Differential Scanning Calorimetry: Thermal 
characteristics of atenolol, β-cyclodextrin, and an 
inclusion complex of atenolol-β-cyclodextrin were 
studied using Mettler Toledo differential scanning 
calorimeter. The scanning rate was 10°C/min and 
the scanning was conducted between 40°C until 
200 °C 
18
.  
Powder X-Ray Diffraction (XRD): The 
crystallographic state of atenolol, β-cyclodextrin, 
and an inclusion complex of atenolol-β-
cyclodextrin was investigated using X-ray 
diffractometer (Phillips) in the range 2Ө (5-50°) at 
room temperature 
14
. 
Scanning Electron Microscopy (SEM): The 
surface morphology of atenolol, β-cyclodextrin, 
and an inclusion complex of atenolol-β-
cyclodextrin was observed by a scanning electron 
microscope. The samples were coated with gold to 
provide a conductive layer for observing images at 
15 KV.  
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Drug Content Analysis of atenolol-β-
cyclodextrin Inclusion Complex: The drug 
content in the atenolol-β-cyclodextrin inclusion 
complex was determined by preparing the inclusion 
complex powder equivalent to 25 mg of atenolol. 
The powder then was dissolved and extracted by 
acetate buffer pH 4,6 in a 100 ml volumetric flask. 
The solution then filtrated through the Whatman 
no. 41 filter paper. 10 ml of the filtrate was pipette 
and transferred into a 25 ml volumetric flask, 
diluted with acetate buffer pH 4.6. The 
concentration of atenolol was determined by 
measuring the absorbance λ 274 nm, using a UV-
Visible double beam spectrophotometer (Shimadzu 
UV-1800). 
Dissolution Test of atenolol-β-cyclodextrin 
Inclusion Complex: Dissolution test of inclusion 
complex was studied the USP apparatus II (Paddle 
method) in the Hanson
®
 dissolution apparatus at 50 
rpm for 60 min. Dissolution studies were carried 
out using 900 ml of acetate buffer pH 4.6 as a 
dissolution medium. The dissolution medium was 
maintained at 37 ± 0.5 °C. The samples of 
dissolution medium (10 ml) were withdrawn at 
specified time intervals (2, 4, 6, 8, 10, 15, 30, 45 
and 60 min). The concentration of atenolol in the 
samples of the dissolution medium was analyzed 
using UV-visible, double beam spectrophotometer 
(Shimadzu UV-1800) at λ 274 nm. The dissolution 
parameters were calculated from this test.  
TABLE 1: FORMULA OF ATENOLOL-β-CYCLO-
DEXTRIN ORALLY DISINTEGRATING TABLETS 
Preparation of Powder Mixture of Orally 
Disintegrating Tablets of atenolol-β-
cyclodextrin: The powder mixture was prepared 
by mixing several components such as atenolol-β-
cyclodextrin inclusion complex, Aerosil
®
, Avicel
®
 
PH 102, crospovidone, aspartame, manitol DC, and 
mint flavor for 10 min in tumbling mixer. The 
composition of an orally disintegrating tablet of 
atenolol-β-cyclodextrin tabulated in Table 1. The 
powder mixture then was evaluated before the 
compression step (pre-compression test). 
Pre Compression Evaluation of the Powder 
Mixture: The powder mixture of orally 
disintegrating tablets of atenolol was evaluated by 
several parameters such as bulk density, tapped 
density, compressibility, Hausner ratio, flowability, 
angle of repose, and moisture content. 
Bulk Density: Bulk density of powder mixture 
calculates by dividing the total mass of powder 
mixture (m) and the bulk volume of the powder 
(Vb). Bulk density was measured by pouring 40 
grams of powder mixture into a measuring 
cylinder. The volume of the powder mixture was 
recorded, then the bulk density was calculated 
using equation 
19
: 
Bulk density = m / Vb 
Where m is the mass of powder mixture, Vb is the 
bulk volume of the powder. 
Tapped Density: Tapped density of the powder 
mixture was determined using the tapping machine. 
The powder mixture was poured into a measuring 
cylinder and transferred into the tapping machine to 
evaluate the volume of the powder (Vt) after being 
tapped 500 times in tapping machine 
20
. The tapped 
volume (Vt) was noted and the tapped density was 
determined by this formula  
Flowability and Angle of Repose: The powder 
mixture (± 100 g) was poured through a wide 
funnel that raised vertically to determine the angle 
of repose and flow speed of the powder mixture.  
The height of the heap (h) and the radius of the 
base (r) were recorded, then the angle of repose 
was determined according to this formula:  
Tan θ = h / r 
Where θ is the angle of repose, h is the height of 
the heap, and r is the radius of the heap in cm.  
Time for the powder mixture to fall down through a 
funnel was used to calculate the flow speed of the 
powder mixture.  
Components Total per tablet (mg) 
Atenolol-β-cyclodextrin 133.41 
Crospovidone 30 
Avicel PH 102® 94.88 
Manitol DC 23.88 
Aspartame 9 
Mint flavor 3 
Magnesium stearate 1.5 
Talk 3 
Aerosil 200® 1.5 
Total 400 
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Compressibility Index and Hausner Ratio: The 
determination of the compressibility index and 
Hausner ratio are performed to evaluate the 
flowability of the powder. The compressibility 
index can be calculated by comparing the bulk 
density (Db) and tapped density (Dt) of the powder 
21
.  The calculation of the compressibility index has 
been performed utilizing this equation: 
Compressibility index = Dt – Db / Dt × 100 
Where Dt is the tapped density of the powder and 
Db is the bulk density of the powder. 
Hausner ratio is an indirect index to predict powder 
flow 
20
. Hausner ratio can be calculated by the 
following formula. 
Hausner ratio = Dt / Db 
Where Dt is the tapped density of the powder and 
Db is the bulk density of the powder. 
Moisture Content: The moisture content of the 
powder was determined by analyzing 
approximately 5 g of the powder. This evaluation 
was done by using the moisture content analyzer. 
The moisture content of the powder can be 
calculated using this equation: 
% MC = W – Wo / Wo × 100% 
Where W is the weight of wet mass and Wo is the 
weight of dry mass 
Preparation of Atenolol Orally Disintegrating 
Tablets: The powder mixture was lubricated and 
then prepared for the compression process. The 
compression process was conducted by compress 
the powder mixture using the Erweka® tablet 
compression machine. The powder was compressed 
into 300 mg tablet using 11 mm flat punches.  
Post Compression Evaluation: Orally 
disintegrating tablets of atenolol-β-cyclodextrin 
tablets were evaluated for organoleptic, dimension, 
hardness, friability, wetting time, water absorption 
ratio, in-vitro dispersion time, disintegration, drug 
content, and dissolution. 
Organoleptic: The orally disintegrating tablets 
were inspected in several parameters such as color, 
shape and taste.  
Dimension: The dimension of the tablets was 
evaluated by vernier caliper to measure the 
thickness and diameter of 10 tablets. Evaluation of 
the tablet dimension was conducted to ensure the 
uniformity of tablet size and predict the problem 
during the compression process.  
Hardness: The hardness or crushing strength of the 
tablets was determined using a Monsanto hardness 
tester. The force required to break a tablet in the 
diametric axis was recorded as the hardness of the 
tablets 
21
.  
Friability: Weighed amount of dedusted tablets 
equal to 6.5 grams were subjected to the rotating 
drum of ERWEKA
®
 rolling and impact durability 
tester. These tablets were placed in the rolling and 
impact durability tester at 25 rpm for 4 min 
22
. % 
Friability was calculated by this following 
equation: 
% Friability = W1 - W2 / W1 × 100 
Where W1 was the weight of the tablet before the 
tablets subjected to the friability test and W2 was 
the weight of the tablet after the friability test. 
Wetting Time and Water Absorption Ratio: 
Wetting time test was conducted to predict the 
hydrophilicity and the penetration rate of water into 
the structure of the tablets. Orally disintegrating 
tablet of atenolol-β-cyclodextrin was placed 
carefully on the surface of filter paper containing 
10 ml eosin solutions. The time of eosin solution to 
reach the surface of the tablets was determined 
23
. 
The water absorption ratio was also determined 
during this test through the amount of the water 
which is penetrating into the inner structure of the 
tablet. Water absorption ratio (R) was determined 
using this equation:  
R = Wa – Wb / Wb × 100 
Where Wb and Wa were tablet weight before and 
after the water absorption test 
In-vitro dispersion time: In-vitro dispersion time 
test was conducted to evaluate the ability of orally 
disintegrating tablets to disperse in the small 
amount volume of saliva. One tablet was placed in 
a tube containing 10 ml of simulated saliva 
solutions (phosphate buffer pH 6.8 with 
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temperature 37 ± 0.5 °C). The time for the tablets 
dispersed completely was determined 
24
. 
In-vitro Disintegration Time: The disintegration 
test was performed using the method which has 
been stated in the compendia. Six tablets were 
placed in each tube of the USP disintegration 
apparatus. The apparatus was equipped with 900 ml 
distilled water maintained at 37 ± 0.5 °C as the 
immersion fluid. In-vitro disintegration time of the 
tablets was determined and recorded 
25
.  
Drug Content: Twenty tablets were powdered 
using a mortar and a stamper. The powder sample 
(equivalent to 25 mg of atenolol) was weighed 
accurately and dissolved in 10 ml of methanol. This 
solution then extracted using acetate buffer pH 4.6 
in a 100 ml volumetric flask. The filtrate of this 
solution then was transferred in a 25 ml volumetric 
flask and diluted using acetate buffer pH 4.6. The 
concentration of atenolol in this solution was 
assayed by a UV-Visible double beam 
spectrophotometer, then the drug content in each 
tablet was calculated 
19, 26
.  
Dissolution Test: The dissolution test was 
performed using USP dissolution testing apparatus 
II at 50 rpm for 120 min. The dissolution medium 
was acetate buffer pH 4.6 and the temperature was 
maintained at 37 ± 0.5 °C. An aliquot (10 ml) of 
the dissolution medium was sampled at a specific 
time interval. The aliquot was replaced with fresh 
acetate buffer pH 4.6 in each sampling interval. 
The amount of atenolol dissolved in each time 
interval was analyzed by UV-visible, double beam 
spectrophotometer (Shimadzu UV-1800) at λ 274 
nm. The dissolution parameters of the tablets were 
determined 
26
.  
RESULTS AND DISCUSSION: 
Characterization of atenolol-β-cyclodextrin 
Inclusion Complex: The atenolol-β-cyclodextrin 
inclusion complex was found to be white powders 
and no odor. 
Fourier Transform Infrared (FT-IR) 
Spectrophotometry: Fourier transform infrared 
(FT-IR) study was conducted to evaluate the 
interaction between atenolol and β-cyclodextrin. 
This study also predicted the formation of a new 
bond between atenolol and β-cyclodextrin in the 
inclusion complex. An infrared spectrum of 
atenolol, β-cyclodextrin, physical mixture of 
atenolol-β-cyclodextrin, and an inclusion complex 
of atenolol- β-cyclodextrin can be seen in Fig. 1. 
 
FIG. 1: INFRARED SPECTRUM OF INCLUSION COMPLEXES OF ATENOLOL-β-CYCLODEXTRIN (A) INFRARED 
SPECTRUM OF ATENOLOL (B) INFRARED SPECTRUM OF β-CYCLODEXTRIN (C) INFRARED SPECTRUM OF 
PHYSICAL MIXTURE OF ATENOLOL-Β-CYCLODEXTRIN (D) INFRARED SPECTRUM OF AN INCLUSION 
COMPLEX ATENOLOL-β-CYCLODEXTRIN BY KNEADING METHOD (E) INFRARED SPECTRUM OF AN 
INCLUSION COMPLEX ATENOLOL-β-CYCLODEXTRIN BY SOLVENT EVAPORATION METHOD 
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Infrared spectrum of pure atenolol showed peaks in 
3354.57 cm
-1
 and 3173.29 cm
-1
 indicated -CO-NH 
group, 2964.05 cm
-1
 (=CH), 1636.03 cm
-1
 (-C=O, 
NH primer) and 1515,78 cm
-1
 (-N-C=O, NH 
secondary). As shown in the figure, atenolol had a 
carbonyl band of 1725-1685 cm
-1
. Atenolol also 
showed the carbonyl band in 1725-1685 cm
-1
. The 
infrared spectrum of the physical mixture revealed 
no significant change regarding the specific peaks 
of atenolol. Whereas, the inclusion complex, which 
is prepared by kneading and a solvent evaporation 
method performed a significant decrease of the 
carbonyl band intensity. This phenomenon can be 
predicted because of the intermolecular hydrogen 
bonds between atenolol and β-cyclodextrin. This 
condition caused by the restriction of atenolol 
packing in cyclodextrin cavity 
27
. Moreover, in 
inclusion complexes that had been prepared by 
kneading and solvent evaporation method, two 
functional groups (-CO-NH) had been bounded by 
functional OH groups of β-cyclodextrin through 
hydrogen bonding 
27
. The sharp peak of atenolol at 
3354 cm
-1
 broadened in the inclusion complex 
spectrum. Moreover, peak in wavelength 3174cm
-1
, 
resulting from -NH vibrations in atenolol structure 
was disappeared in the atenolol-β-cyclodextrin 
inclusion complex spectrum. This condition caused 
by a complex interaction with β-cyclodextrin 
Differential Scanning Calorimetry (DSC): 
Thermal behavior of atenolol, physical mixture of 
atenolol-β-cyclodextrin, and an inclusion complex 
of atenolol-β-cyclodextrin were studied in order to 
analyze the complex formation. The DSC 
thermogram of atenolol, physical mixture of 
atenolol-β-cyclodextrin, and an inclusion complex 
of atenolol-β-cyclodextrin are shown in Fig. 2. 
 
FIG. 2: DSC THERMOGRAM OF (A) DSC THERMOGRAM OF ATENOLOL (B) DSC THERMOGRAM OF β-CYCLODEXTRIN 
(C) DSC THERMOGRAM OF PHYSICAL MIXTURE OF ATENOLOL-β-CYCLODEXTRIN (D) DSC THERMOGRAM OF 
INCLUSION COMPLEX ATENOLOL-β-CYCLODEXTRIN BY KNEADING METHOD (E) DSC THERMOGRAM OF AN 
INCLUSION COMPLEX ATENOLOL-β-CYCLODEXTRIN BY SOLVENT EVAPORATION METHOD 
The DSC thermogram of atenolol showed that this 
molecule has an endothermic peak at 153.50 °C, 
according to its melting point. The β-cyclodextrin 
showed a broad endothermic peak, which is 
approximately located at 122.43 °C due to the 
release of water molecules from the structure. 
Physical mixture showed two endothermic peaks at 
120.89 ºC and 151.46 ºC.  
Inclusion complex, which was prepared by 
kneading method showed two endothermic peaks at 
121.27 ºC and 149.71 ºC, while the solvent 
evaporation method produces the inclusion 
complex which revealed one endothermic peak at 
146.68 ºC. The complete disappearance of atenolol 
indicates that the inclusion complex is formed with 
optimum condition 
18
. 
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Powder X-Ray diffraction (XRD): The X-ray 
diffraction patterns of pure atenolol, as well as the 
atenolol-β-cyclodextrin inclusion complexes 
obtained by using kneading method and solvent 
evaporation method, are represented in Fig. 3.  
 
FIG. 3: X-RAY DIFFRACTION PATTERN OF (A) ATENOLOL (B) β-CYCLODEXTRIN (C) PHYSICAL MIXTURE OF 
ATENOLOL-β-CYCLODEXTRIN (D) INCLUSION COMPLEX OF ATENOLOL-β-CYCLODEXTRIN BY KNEADING METHOD 
(E) INCLUSION COMPLEX OF ATENOLOL-β-CYCLODEXTRIN BY THE SOLVENT EVAPORATION METHOD 
Analysis of the crystallographic aspect was 
conducted to determine the difference of the crystal 
structure of the inclusion complex compare to pure 
drug. The results showed that there was a decrease 
in the peak intensity of atenolol in inclusion 
complex formation. The highest reduction of the 
peak intensity of atenolol showed by the inclusion 
complex, which was prepared using the solvent 
evaporation method. Inclusion complex 
characterized as a new solid phase with lower 
crystallinity compared to the pure drug.  
  
   
FIG. 4: SCANNING ELECTRON MICROSCOPY (SEM) IMAGES OF (A) ATENOLOL (B) β-CYCLODEXTRIN (C) PHYSICAL 
MIXTURE OF ATENOLOL-β-CYCLODEXTRIN (D) INCLUSION COMPLEX OF ATENOLOL-β-CYCLODEXTRIN BY 
KNEADING METHOD (E) INCLUSION COMPLEX OF ATENOLOL-β-CYCLODEXTRIN BY THE SOLVENT EVAPORATION 
METHOD 
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Scanning Electron Microscopy (SEM): The SEM 
study showed the morphology and microscopy 
photography of the drug and its inclusion complex. 
The representative images are shown in Fig. 4. 
The shape of pure drug particles was irregular. The 
physical mixture images showed that only a small 
amount of atenolol which was attached to the 
surface of β-cyclodextrin. The inclusion complex, 
which is prepared by the kneading method 
observed that the drug particles attach at the surface 
of β-cyclodextrin. Moreover, the inclusion 
complex, which is prepared by the solvent 
evaporation method showed that atenolol particles 
attached and incorporated into β-cyclodextrin. The 
solvent evaporation inclusion complex was poor of 
crystal structure, lack distinct crystal faces, and 
incorporated completely in β-cyclodextrin structure 
28
. 
Drug Content: UV spectrophotometry was used to 
determine the drug content of the inclusion 
complex of atenolol-β-cyclodextrin. The results 
showed that the drug content of physical mixture 
was 91.47 ± 1.22%, the inclusion complex, which 
was produced by kneading method was 92.59 ± 
0.90%, and the inclusion complex, which was 
produced by solvent evaporation method was 95.40 
± 0.97%. 
Dissolution Test of atenolol-β-cyclodextrin 
Inclusion Complex: Dissolution profile of 
inclusion complex, which was prepared by physical 
mixing, kneading method, and solvent evaporation 
method. The dissolution profiles are as shown in 
Fig. 5.  
 
FIG. 5: DISSOLUTION PROFILE OF INCLUSION 
COMPLEX ATENOLOL-β-CYCLODEXTRIN WHICH 
MADE BY PHYSICAL MIXING, KNEADING METHOD, 
AND SOLVENT EVAPORATION METHOD 
The Dissolution parameter of the inclusion 
complex shown in Table 2.  
TABLE 2: DISSOLUTION PARAMETER OF INCLUSION COMPLEX 
Method %Q (30 min) TQ% (min) AUC (0-60 min) %ED Kr (min) 
Physical mixture 91.96% ± 0.00 4.49 ± 0.34 5321.93 ± 13.75 88.70% ± 0.23 0.0046 ± 0.00 
Kneading 94.05 ± 0.45 7.61 ± 1.65 5400.46 ± 25.72 90.01% ± 0.43 0.0138 ± 0.00 
Solvent evaporation 99.56 ± 0.45 5.19 ± 1.62 5710.12 ± 14.54 95.17% ± 0.24 0.0537 ± 0.01 
 
The dissolution profiles of physical mixture and 
inclusion complexes showed that the solvent 
evaporation method exhibited a little faster 
dissolution rate than the physical mixture and 
produced by the kneading method. An Inclusion 
complex of atenolol-β-cyclodextrin prepared by the 
solvent evaporation method is promising to develop 
into orally disintegrating tablets. The inclusion 
complex, which was produced by the solvent 
evaporation method was continued to develop into 
orally disintegrating tablets.  
Pre Compression Evaluation: Precompression 
evaluation was conducted to predict the ability of 
powder mixture to be compressed into an orally 
disintegrating tablet. The ability of the powder to 
flow was a parameter that was evaluated during this 
test. The flowability of the powder blend also must 
be determined to predict the ability of powder 
blend to fulfill the dies during the compression 
stage. The flow properties of the powder mixture 
can be determined by analyzing the compressibility 
index (%) and Hausner ratio 
28
. The results of the 
compressibility index and Hausner ratio revealed 
that the powder mixture had poor flow character.  
The results of flow velocity and angle of repose 
were found that the powder can not flow well in a 
glass funnel. This was due to the high percentage of 
fines in the powder mixture. The powder mixture 
which had a high percentage of fines, was more 
adhesive or cohesive. The flow of the powder in 
this situation was not influenced by gravitation 
force 
28
. This problem can be solved by decreasing 
the fines percentage and controlling the particle 
size distribution.  
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Moisture content evaluation of powder mixture was 
conducted to determine that the powder mixture 
had sufficient moisture content to be compressed. 
The results showed that the powder mixture had a 
high moisture content (6.21% ± 0.23). The high 
moisture content of powder mixture probably 
caused by the excipient which was hygroscopic, 
such as β-cyclodextrin, crospovidone, and Avicel® 
PH 102. The powder mixture which had high 
humidity will be more cohesive so that this mixture 
did not flow well. Therefore the weighing process, 
the mixing process, and the tableting process must 
be conducted in a room in which the humidity and 
temperature are controlled well. The results of the 
pre-compression evaluation are tabulated in Table 3.  
TABLE 3: THE RESULTS OF PRE COMPRESSION 
EVALUATION OF ATENOLOL-β-CYCLODEXTRIN 
ORALLY DISINTEGRATING TABLETS 
Parameters Result 
Compressibility index (%) 33.67 ± 0.00% 
Hausner Ratio 1.508 ± 0.000 
Moisture content (%) 6.21 ± 0.23% 
Post Compression Evaluation: Atenolol orally 
disintegrating tablets were white, round shape, no 
odor, sweet and mint flavor. Tablet means 
thickness and diameter were almost uniform in the 
formula. Orally disintegrating tablets of atenolol-β-
cyclodextrin performed good mechanical strength 
during hardness test. The hardness of orally 
disintegrating tablets of atenolol-β-cyclodextrin 
was 2.49 ± 0.41 kg. The specification of tablet 
hardness in orally disintegrating tablets is 2.0-4.0 
kg 
29
. Friability and abrasion values of orally 
disintegrating tablets of atenolol were below 1%. 
This result indicating that orally disintegrating 
tablets of atenolol-cyclodextrin have good 
mechanical resistance. The results of the post-
compression evaluation are tabulated in Table 4.  
TABLE 4: POST COMPRESSION PARAMETERS OF 
ATENOLOL-β-CYCLODEXTRIN ORALLY DISINTE-
GRATING TABLETS 
Parameter Result 
Organoleptic White, round shape, no odor, 
sweet and mint flavor 
Drug content 100.01 ± 1.1% 
Diameter 1.10 ± 0.00 cm 
Thickness 0.41 ± 0.00 cm 
Hardness 2.49 ± 0.41 kg 
Disintegration time 8.17 ± 0.41 sec 
Dispersion time 45.33 ± 0.58 sec 
Friability 0.26 ± 0.21% 
The wetting time for orally disintegrating tablets of 
atenolol-β-cyclodextrin was 124.67 ± 3.79 sec. The 
faster the wetting time of the tablets, the faster the 
tablets will be disintegrated when contact with the 
media. The water absorption ratio test was 
conducted to predict the amount of water that can 
be absorbed by orally disintegrating tablets. Orally 
disintegrating tablets which have lower water 
absorption ratio were more preferable to develop. 
This was due to the orally disintegrating tablets 
only need a small amount of water to disperse in 
the media 
30
. Orally disintegrating tablets of 
atenolol-β-cyclodextrin posses appropriate wetting 
time and water absorption ratio.  
The disintegration time of atenolol-β-cyclodextrins 
tablets was 8.17 ± 0.41 seconds. These results 
showed that orally disintegrating tablets of 
atenolol-β-cyclodextrins fulfill the specification 
which has been stated in compendia (<1 min) 
31
. In-
vitro dispersion time was also conducted to predict 
the ability of orally disintegrating tablets to be 
dispersed in a small amount of saliva in the oral 
cavity. Orally disintegrating tablets of atenolol-β-
cyclodextrins dispersed in 45.33 ± 0.58 seconds. 
Crospovidone characteristic which promotes 
capillary activity and hydration enhances the tablets 
to disperse rapidly without forming gel formation 
on the surface of the tablets 
32
.  
 
FIG. 6: DISSOLUTION PROFILE OF ORALLY 
DISINTEGRATING TABLETS OF ATENOLOL-β-
CYCLODEXTRIN 
The dissolution profile of orally disintegrating 
tablets of atenolol-β-cyclodextrin showed in Fig. 6. 
The results from the dissolution study showed that 
orally disintegrating tablets atenolol-β-cyclodextrin 
meet the specification of compendia. The 
specification stated that the minimum amount of 
drug dissolved in 30 min is 85%.  
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The amount of drug dissolved from this formula 
was 92.22%, so it can be concluded that this orally 
disintegrating tablet met the specification.  
CONCLUSION: The results from this study 
showed that the solvent evaporation method 
produces the best physicochemical characteristics 
of the inclusion complex of atenolol-β-
cyclodextrin. Consequently, the solvent 
evaporation method was chosen to produce the 
inclusion complex of atenolol-β-cyclodextrin which 
further developed into orally disintegrating tablets. 
Orally disintegrating tablets of atenolol-β-
cyclodextrin with sufficient mechanical strength, 
fast dispersion and disintegration time, and the 
acceptable taste was produced from this study.  
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